|Classification and external resources|
Glioma in the left parietal lobe (brain CT scan), WHO grade 2.
A glioma is a type of tumor that starts in the brain or spine. It is called a glioma because it arises from glial cells. The most common site of gliomas is the brain. Gliomas make up about 30% of all brain and central nervous system tumors and 80% of all malignant brain tumors.
Gliomas are classified by cell type, by grade, and by location.
By type of cell
Gliomas are named according to the specific type of cell they share histological features with, but not necessarily originate from. The main types of gliomas are:
- Ependymomas—ependymal cells.
- Astrocytomas—astrocytes (glioblastoma multiforme is a malignant astrocytoma and the most common primary brain tumor among adults).
- Brainstem glioma — develop in the brain stem
- Optic nerve glioma — develop in or around the optic nerve
- Mixed gliomas, such as oligoastrocytomas, contain cells from different types of glia.
- Low-grade gliomas [WHO grade II] are well-differentiated (not anaplastic); these tend to exhibit benign tendencies and portend a better prognosis for the patient. However, they have a uniform rate of recurrence and increase in grade over time so should be classified as malignant.
- High-grade [WHO grade III–IV] gliomas are undifferentiated or anaplastic; these are malignant and carry a worse prognosis.
Of numerous grading systems in use, the most common is the World Health Organization (WHO) grading system for astrocytoma, under which tumors are graded from I (least advanced disease—best prognosis) to IV (most advanced disease—worst prognosis).
- supratentorial: above the tentorium, in the cerebrum, mostly found in adults (70%).
- infratentorial: below the tentorium, in the cerebellum, mostly found in children (70%).
- pontine: located in the pons of the brainstem. The brainstem has three parts (pons, midbrain and medulla); the pons controls critical functions such as breathing, making surgery on these extremely dangerous.
Signs and symptoms
Symptoms of gliomas depend on which part of the central nervous system is affected. A brain glioma can cause headaches, nausea and vomiting, seizures, and cranial nerve disorders as a result of increased intracranial pressure. A glioma of the optic nerve can cause visual loss. Spinal cord gliomas can cause pain, weakness, or numbness in the extremities. Gliomas do not metastasize by the bloodstream, but they can spread via the cerebrospinal fluid and cause "drop metastases" to the spinal cord.
A child who has a subacute disorder of the central nervous system that produces cranial nerve abnormalities (especially of cranial nerve VII and the lower bulbar nerves), long-tract signs, unsteady gait secondary to spasticity, and some behavioral changes is most likely to have a pontine glioma.
Gliomas have been correlated to the electromagnetic radiation from cell phones, and a link between the cancer and cell phone usage was considered possible, though several large studies have found no conclusive evidence. Experiments designed to test such a link gave negative results. Most glioblastomas are infected with cytomegalovirus, which speeds the development of tumors.
Germ-line (inherited) polymorphisms of the DNA repair genes ERCC1, ERCC2 (XPD) and XRCC1 increase the risk of glioma. This indicates that altered or deficient repair of DNA damage contributes to the formation of gliomas. DNA damages are a likely major primary cause of progression to cancer in general. Excess DNA damages can give rise to mutations through translesion synthesis. Furthermore, incomplete DNA repair can give rise to epigenetic alterations or epimutations. Such mutations and epimutations may provide a cell with a proliferative advantage which can then, by a process of natural selection, lead to progression to cancer.
Epigenetic repression of DNA repair genes is often found in progression to sporadic glioblastoma. For instance, methylation of the DNA repair gene MGMT promoter was observed in 51.3% to 66% of glioblastoma specimens. In addition, in some glioblastomas, the MGMT protein is deficient due to another type of epigenetic alteration. MGMT protein expression may also be reduced due to increased levels of a microRNA that inhibits the ability of the MGMT messenger RNA to produce the MGMT protein. Zhang et al. found, in the glioblastomas without methylated MGMT promoters, that the level of microRNA miR-181d is inversely correlated with protein expression of MGMT and that the direct target of miR-181d is the MGMT mRNA 3’UTR (the three prime untranslated region of MGMT messenger RNA).
Epigenetic reductions in expression of another DNA repair protein, ERCC1, were found in an assortment of 32 gliomas. For 17 of the 32 (53%) of the gliomas tested, ERCC1 protein expression was reduced or absent. In the case of 12 gliomas (37.5%) this reduction was due to methylation of the ERCC1 promoter. For the other 5 gliomas with reduced ERCC1 protein expression, the reduction could have been due to epigenetic alterations in microRNAs that affect ERCC1 expression.
When expression of DNA repair genes is reduced, DNA damages accumulate in cells at a higher than normal level, and such excess damages cause increased frequencies of mutation. Mutations in gliomas frequently occur in either isocitrate dehydrogenase (IDH) 1 or 2 genes. One of these mutations (mostly in IDH1) occurs in about 80% of low grade gliomas and secondary high-grade gliomas. Wang et al. pointed out that IDH1 and IDH2 mutant cells produce an excess metabolic intermediate, 2-hydroxyglutarate, which binds to catalytic sites in key enzymes that are important in altering histone and DNA promoter methylation. Thus, mutations in IDH1 and IDH2 generate a “DNA CpG island methylator phenotype or CIMP” that causes promoter hypermethylation and concomitant silencing of tumor suppressor genes such as DNA repair genes MGMT and ERCC1. On the other hand, Cohen et al. pointed out that mutations in IDH1 or IDH2 can cause increased oxidative stress. Increased oxidative damage to DNA could be mutagenic. Thus, IDH1 or IDH2 mutations act as driver mutations in glioma carcinogenesis, though it is not clear by which role they are primarily acting. A study, involving 51 patients with brain gliomas who had two or more biopsies over time, showed that mutation in the IDH1 gene occurred prior to the occurrence of a p53 mutation or a 1p/19q loss of heterozygosity, indicating that an IDH1 mutation is an early driver mutation.
High-grade gliomas are highly-vascular tumors and have a tendency to infiltrate. They have extensive areas of necrosis and hypoxia. Often tumor growth causes a breakdown of the blood–brain barrier in the vicinity of the tumor. As a rule, high-grade gliomas almost always grow back even after complete surgical excision, and so are commonly called recurrent cancer of the brain.
On the other hand, low-grade gliomas grow slowly, often over many years, and can be followed without treatment unless they grow and cause symptoms.
Several acquired (not inherited) genetic mutations have been found in gliomas. Tumor suppressor protein 53 (p53) is mutated early in the disease. p53 is the "guardian of the genome," which, during DNA and cell duplication, makes sure that the DNA is copied correctly and destroys the cell (apoptosis) if the DNA is mutated and can't be fixed. When p53 itself is mutated, other mutations can survive. Phosphatase and tensin homolog (PTEN), another protein that also helps destroy cells with dangerous mutations, is itself lost or mutated. Epidermal growth factor receptor (EGFR), a growth factor that normally stimulates cells to divide, is amplified and stimulates cells to divide too much. Together, these mutations lead to cells dividing uncontrollably, a hallmark of cancer. Recently, mutations in IDH1 and IDH2 were found to be part of the mechanism and associated with a more favorable prognosis. The IDH1 and IDH2 genes are significant because they are involved in the citric acid cycle in mitochondria. Mitochondria are involved in apoptosis. Furthermore, the altered glycolysis metabolism in some cancer cells leads to low oxygen (hypoxia). The normal response to hypoxia is to stimulate the growth of new blood vessels (angiogenesis). So these two genes may contribute to both the lack of apoptosis and vascularization of gliomas.
Treatment for brain gliomas depends on the location, the cell type and the grade of malignancy. Often, treatment is a combined approach, using surgery, radiation therapy, and chemotherapy. The radiation therapy is in the form of external beam radiation or the stereotactic approach using radiosurgery. Spinal cord tumors can be treated by surgery and radiation. Temozolomide is a chemotherapeutic drug that is able to cross the blood–brain barrier effectively and is currently being used in therapy for high-grade tumors.
A 2007 meta-analysis compared surgical resection and biopsy as the initial surgical management option. Results show that there is insufficient evidence to make a reliable decision. For high-grade gliomas, a 2003 meta-analysis compared radiotherapy with radiotherapy and chemotherapy. It showed a small but clear improvement from using chemotherapy with radiotherapy. In low grade gliomas a comparative study found that treatment at a center that favored early surgical resection was associated with better overall survival than treatment at a center that favored biopsy and watchful waiting. For Glioblastoma Multiforme, a 2008 meta-analysis showed that Temozolomide is an effective treatment for "prolonging survival and delaying progression as part of primary therapy without impacting on QoL and with a low incidence of early adverse events."
Gliomas are rarely curable. The prognosis for patients with high-grade gliomas is generally poor, and is especially so for older patients. Of 10,000 Americans diagnosed each year with malignant gliomas, about half are alive one year after diagnosis, and 25% after two years. Those with anaplastic astrocytoma survive about three years. Glioblastoma multiforme has a worse prognosis with less than a 12-month average survival after diagnosis, though this has extended to 14 months with more recent treatments .
For low-grade tumors, the prognosis is somewhat more optimistic. Patients diagnosed with a low-grade glioma are 17 times as likely to die as matched patients in the general population. The age-standardized 10-year relative survival rate was 47%. One study reported that low-grade oligodendroglioma patients have a median survival of 11.6 years; another reported a median survival of 16.7 years.
Diffuse intrinsic pontine glioma
Diffuse intrinsic pontine glioma primarily affects children, usually between the ages of 5 and 7. The median survival time with DIPG is under twelve months. Surgery to attempt tumour removal is usually not possible or advisable for DIPG. By their very nature, these tumours invade diffusely throughout the brain stem, growing between normal nerve cells. Aggressive surgery would cause severe damage to neural structures vital for arm and leg movement, eye movement, swallowing, breathing, and even consciousness.[unreliable medical source?] Trials of drug candidates have been unsuccessful.
- Mamelak AN, Jacoby DB (March 2007). "Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601)". Expert Opin Drug Deliv 4 (2): 175–86. doi:10.1517/17425247.4.2.175. PMID 17335414.
- Goodenberger ML, Jenkins RB (2012). "Genetics of adult glioma". Cancer Genet. doi:10.1016/j.cancergen.2012.10.009.
- PRETEST pediatrics pg 224
- Reuss, D; von Deimling, A (2009). "Hereditary tumor syndromes and gliomas.". Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 171: 83–102. doi:10.1007/978-3-540-31206-2_5. PMID 19322539.
- "IARC classifies radiofrequency electromagnetic fields as possibly carcinogenic to humans" (Press release). IARC. 31 May 2011.
- Benson, Victoria; Kristin Pirie; Joachim Schüz; Gillian K Reeves; Valerie Beral; Jane Green (23 March 2013). "Mobile phone use and risk of brain neoplasms and other cancers: prospective study". International Journal of Epidemiology 42 (3): 792–802. doi:10.1093/ije/dyt072. Retrieved 8 May 2013.
- Michaelis M, Baumgarten P, Mittelbronn M, Driever PH, Doerr HW, Cinatl J, Jr (February 2011). "Oncomodulation by human cytomegalovirus: novel clinical findings open new roads.". Medical microbiology and immunology 200 (1): 1–5. doi:10.1007/s00430-010-0177-7. PMID 20967552.
- Barami, K (July 2010). "Oncomodulatory mechanisms of human cytomegalovirus in gliomas.". Journal of Clinical Neuroscience 17 (7): 819–23. doi:10.1016/j.jocn.2009.10.040. PMID 20427188.
- Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor Dallas SR, Smit M, Soroceanu L, Cobbs CS; HCMV and Gliomas Symposium (Mar 2012). "Consensus on the role of human cytomegalovirus in glioblastoma". Neuro Oncol 14 (3): 246–55. doi:10.1093/neuonc/nor227. PMC 3280809. PMID 22319219.
- Adel Fahmideh M, Schwartzbaum J, Frumento P, Feychting M (June 2014). "Association between DNA repair gene polymorphisms and risk of glioma: A systematic review and meta-analysis". Neuro-oncology 16 (6): 807–14. doi:10.1093/neuonc/nou003. PMID 24500421.
- Bernstein C, Prasad AR, Nfonsam V, Bernstein H. (2013). DNA Damage, DNA Repair and Cancer, New Research Directions in DNA Repair, Prof. Clark Chen (Ed.), ISBN 978-953-51-1114-6, InTech, http://www.intechopen.com/books/new-research-directions-in-dna-repair/dna-damage-dna-repair-and-cancer
- Cuozzo C, Porcellini A, Angrisano T, Morano A, Lee B, Di Pardo A, Messina S, Iuliano R, Fusco A, Santillo MR, Muller MT, Chiariotti L, Gottesman ME, Avvedimento EV (2007). DNA damage, homology-directed repair, and DNA methylation. PLoS Genet 3(7):e110. PMID 17616978
- O'Hagan HM, Mohammad HP, Baylin SB. Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet 2008;4(8) e1000155. PMID 18704159
- Skiriute D, Vaitkiene P, Saferis V, Asmoniene V, Skauminas K, Deltuva VP, Tamasauskas A (2012). "MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma". BMC Cancer 12: 218. doi:10.1186/1471-2407-12-218. PMC 3404983. PMID 22672670.
- Spiegl-Kreinecker S, Pirker C, Filipits M, Lötsch D, Buchroithner J, Pichler J, Silye R, Weis S, Micksche M, Fischer J, Berger W (January 2010). "O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients". Neuro-oncology 12 (1): 28–36. doi:10.1093/neuonc/nop003. PMC 2940563. PMID 20150365.
- Zhang W, Zhang J, Hoadley K, Kushwaha D, Ramakrishnan V, Li S, Kang C, You Y, Jiang C, Song SW, Jiang T, Chen CC (June 2012). "miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression". Neuro-oncology 14 (6): 712–9. doi:10.1093/neuonc/nos089. PMC 3367855. PMID 22570426.
- Chen HY, Shao CJ, Chen FR, Kwan AL, Chen ZP (April 2010). "Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas". Int. J. Cancer 126 (8): 1944–54. doi:10.1002/ijc.24772. PMID 19626585.
- Narayanan L, Fritzell JA, Baker SM, Liskay RM, Glazer PM (April 1997). "Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2". Proc. Natl. Acad. Sci. U.S.A. 94 (7): 3122–7. doi:10.1073/pnas.94.7.3122. PMC 20332. PMID 9096356.
- Hegan DC, Narayanan L, Jirik FR, Edelmann W, Liskay RM, Glazer PM (December 2006). "Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6". Carcinogenesis 27 (12): 2402–8. doi:10.1093/carcin/bgl079. PMC 2612936. PMID 16728433.
- Tutt AN, van Oostrom CT, Ross GM, van Steeg H, Ashworth A (March 2002). "Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation". EMBO Rep. 3 (3): 255–60. doi:10.1093/embo-reports/kvf037. PMC 1084010. PMID 11850397.
- Cohen AL, Holmen SL, Colman H (May 2013). "IDH1 and IDH2 mutations in gliomas". Curr Neurol Neurosci Rep 13 (5): 345. doi:10.1007/s11910-013-0345-4. PMID 23532369.
- Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, Andersen JB, Jiang W, Savich GL, Tan TX, Auman JT, Hoskins JM, Misher AD, Moser CD, Yourstone SM, Kim JW, Cibulskis K, Getz G, Hunt HV, Thorgeirsson SS, Roberts LR, Ye D, Guan KL, Xiong Y, Qin LX, Chiang DY (June 2013). "Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas". Oncogene 32 (25): 3091–100. doi:10.1038/onc.2012.315. PMC 3500578. PMID 22824796.
- Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP (July 1999). "CpG island methylator phenotype in colorectal cancer". Proc. Natl. Acad. Sci. U.S.A. 96 (15): 8681–6. PMC 17576. PMID 10411935.
- Mojarad EN, Kuppen PJ, Aghdaei HA, Zali MR (2013). "The CpG island methylator phenotype (CIMP) in colorectal cancer". Gastroenterol Hepatol Bed Bench 6 (3): 120–128. PMC 4017514. PMID 24834258.
- Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (April 2009). "IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas". Am. J. Pathol. 174 (4): 1149–53. doi:10.2353/ajpath.2009.080958. PMC 2671348. PMID 19246647.
- Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (19 Feb 2009). "IDH1 and IDH2 mutations in gliomas". N Engl J Med 360 (8): 765–73. doi:10.1056/NEJMoa0808710. PMC 2820383. PMID 19228619.
- Wong ET, Brem S (2007). "Taming glioblastoma: targeting angiogenesis". J. Clin. Oncol. 25 (30): 4705–6. doi:10.1200/JCO.2007.13.1037. PMID 17947716.
- Hart MG, Grant R, Metcalfe SE (2000). "Biopsy versus resection for high grade glioma". In Hart, Michael G. Cochrane Database Syst Rev (2): CD002034. doi:10.1002/14651858.CD002034. PMID 10796847.
- Stewart L, Burdett S; Glioma Meta-analysis Trialists Group (GMT) (2002). "Chemotherapy for high-grade glioma". In Stewart, Lesley. Cochrane Database Syst Rev (3): CD003913. doi:10.1002/14651858.CD003913. PMID 12519620.
- Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K (2008-10-08). "Temozolomide for high grade glioma". In Hart, Michael G. Cochrane Database Syst Rev (4): CD007415. doi:10.1002/14651858.CD007415. PMID 18843749.
- Rob Stein (May 20, 2008). "Malignant Gliomas Affect About 10,000 Americans Annually". Washington Post.
- Smoll N, Gautschi OP, Schatlo B, Schaller K, Weber DC (July 6, 2012). "Relative Survival of Patients with Supratentorial Low Grade Gliomas". Neuro-Oncology.
- Ohgaki H, Kleihues P (June 2005). "Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas". J Neuropathol Exp Neurol. 64 (6): 479–89. PMID 15977639.
- Kebudi R, Cakir FB (Oct 2013). "Management of diffuse pontine gliomas in children: recent developments". Paediatr Drugs 15 (5): 351–62. doi:10.1007/s40272-013-0033-5. PMID 23719782.
- Fisher PG, Breiter SN, Carson BS, Wharam MD, Williams JA, Weingart JD, Foer DR, Goldthwaite PT, Burger PC. A clinicopathologic reappraisal of brainstem tumor classification: identification of pilocytic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer 89:1569-1576, 2000.
- Donaldson SS, Laningham F, Fisher PG. Advances toward an understanding of brain stem gliomas. J Clin Oncol 24:1266-1272, 2006.
- Jansen MH, van Vuurden DG, Vandertop WP, Kaspers GJ (Feb 2012). "Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology". Cancer Treat Rev. 38 (1): 27–35. doi:10.1016/j.ctrv.2011.06.007. PMID 21764221.
- American Brain Tumor Association: Malignant Gliomas
- Brain and Spinal Tumors: Hope Through Research (National Institute of Neurological Disorders and Stroke)
- -2147090429 at GPnotebook
- German Brain Tumor Association
- WHO Classification of Glioma
- Glioma Images MedPix Database